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FGFR2 Abnormalities Underlie a Spectrum of Bone,
Skin, and Cancer Pathologies
Masaru Katoh1
Fibroblast growth factor receptor (FGFR)2 is regulated on the basis of the balance of FGFs, heparan-sulfate
proteoglycans, FGFR2 isoforms, endogenous inhibitors, and microRNAs. FGFR2 signals cross-talk with
hedgehog, bone morphogenetic protein, and other regulatory networks. Some cases of congenital skeletal
disorders with an FGFR2 mutation show skin phenotypes, including acne, cutis gyrata, and acanthosis nigricans.
Gain-of-function mutations or variations of human FGFR2 occur in estrogen receptor-positive breast cancer,
diffuse-type gastric cancer, and endometrial uterine cancer. Oral administration of AZD2171 or Ki23057 inhibits
in vivo proliferation of cancer cells with aberrant FGFR2 activation in rodent therapeutic models. However, loss-
of-function mutations of FGFR2 are reported in human melanoma. Conditional Fgfr2b knockout in the rodent
epidermis leads to increased macrophage infiltration to the dermis and adipose tissue, epidermal thickening
accompanied by basal-layer dysplasia and parakeratosis, and the promotion of chemically induced squamous-
cell carcinoma. Dysregulation of FGFR2 results in a spectrum of bone and skin pathologies and several types of
cancer.
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INTRODUCTION
FGFR1, FGFR2, FGFR3, and FGFR4
genes encode receptors for fibroblast
growth factors (FGFs) that are involved
in fetal morphogenesis, adult tissue
homeostasis, and tumorigenesis (Dailey
et al., 2005; Eswarakumar et al., 2005;
Grose and Dickson, 2005; Wilkie,
2005; Chaffer et al., 2007). The BAG4–
PPAPDC1B–FGFR1–TACC1 locus at
human chromosome 8p11–p12 and
the BAG3–PPAPDC1A–FGFR2–TACC2
locus at human chromosome
10q26.12–q26.13 are syntenic blocks
generated by ancient whole-genome
duplications during vertebrate evolu-
tion (Katoh and Katoh, 2003b; Itoh and
Ornitz, 2004). FGFR1 and FGFR2 are
paralogs in the FGFR gene family.
The FGFR2 gene encodes several
splice variants by alternative splicing
(Dionne et al., 1990; Miki et al., 1991;
Savagner et al., 1994; Katoh and Katoh,
2003a). Fibroblast growth factor receptor
(FGFR)2b and FGFR2c are representative
FGFR2 isoforms among several splice
variants derived from the FGFR2 gene.
FGFR2b, in epithelial cells, and FGFR2c,
in mesenchymal cells, are almost iden-
tical transmembrane-type receptors with
extracellular immunoglobulin-like do-
mains and cytoplasmic tyrosine-kinase
domain. FGFR2b functions as the recep-
tor for FGF1, FGF3, FGF7, FGF10, and
FGF22, whereas FGFR2c functions as the
receptor for FGF1, FGF2, FGF4, FGF6,
FGF9, FGF16, FGF17, FGF18, and
FGF20 (Ornitz et al., 1996; Eswarakumar
et al., 2005; Zhang et al., 2006). As the
latter half of the third immunoglobulin-
like domain of FGFR2b and FGFR2c is
completely different because of alterna-
tive splicing of mutually exclusive exons,
FGFR2b and FGFR2c show distinct
ligand specificity.
Heparan-sulfate proteoglycan is a
scaffolding protein that mediates the
interaction of FGFs and FGFR2 in a
tissue-specific manner (Mohammadi
et al., 2005; Luo et al., 2006). FGFs that
are associated with heparan sulfate
proteoglycan induce dimerization and
autophosphorylation of FGFR2 on Y657
in the activation loop of the tyrosine
kinase domain to release FGFR2 from
autoinhibition (Dailey et al., 2005;
Eswarakumar et al., 2005; Chen et al.,
2007). FGFR2 then phosphorylates
fibroblast growth factor receptor sub-
strate (FRS)2/FRS2a/Sucl-associated neu-
rotrophic factor target 1 (Wang et al.,
1996; Hadari et al., 2001) to recruit
growth factor receptor-bound protein 2
for the activation of the SOS—Ras–Raf—
MEK(MAPK (mitogen-activated protein
kinase)/ERK (extracellular signal-regulated
kinase) kinase)–ERK (extracellular sig-
nal-regulated kinase) or the Gab1–phos-
phoinositide-3 kinase –Akt signaling
cascade. Activated FGFR2 directly re-
cruits phospholipase C-g to catalyze
phosphatidylinositol diphosphate to in-
ositol triphosphate and diacylglycerol.
Inositol triphosphate induces Ca2þ re-
lease from the endoplasmic reticulum,
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whereas diacylglycerol activates protein
kinase C, protein kinase D, or RasGRP
(guanyl nucleotide-releasing protein)
signaling cascades. FGFR2 transduces
FGF signals to Ras-extracellular signal-
regulated kinase, phosphoinositide-3
kinase-Akt, Ca2þ , and diacylglycerol
signaling cascades (Figure 1).
FGFR2 is regulated on the basis of
the balance of FGFs, heparan-sulfate
proteoglycans, FGFR2 isoforms, and
endogenous inhibitors (Figure 1). Spro-
uty inhibits the FGF-extracellular sig-
nal-regulated kinase signaling cascade
at growth factor receptor-bound protein
2 and Raf, whereas dual-specificity
phosphatase inhibits the FGF-extracel-
lular signal-regulated kinase signaling
cascade at extracellular signal-regu-
lated kinase. microRNAs (miRNAs) are
emerging as crucial regulators of var-
ious signaling networks (Bartel, 2004;
Negrini et al., 2007; Grosshans and
Filipowicz, 2008; Katoh and Katoh,
2008). MiR-433 represses translation
of FGF20 in individuals with the
C allele of the rs12720208 single
nucleotide polymorphism (SNP) (Wang
et al., 2008), whereas miR-21 represses
translation of functions of FGFR signal-
ing inhibitor, Spry1 (Thum et al., 2008).
Germline Fgfr2b-knockout mice die
shortly after birth because of multiple-
organ abnormalities, such as agenesis
of the lungs, limbs, anterior pituitary
gland, and thyroid gland and dysgen-
esis of the skin, glandular stomach,
pancreas, and thymus (De Moerlooze
et al., 2000; Revest et al., 2001).
Genetic alterations of FGFR2 at germ-
line or somatic level gives rise to
congenital disorders and acquired dis-
eases through dysregulation of FGFR2
signaling cascades (Grose and Dickson,
2005; Wilkie, 2005; Katoh, 2008).
Genome-wide association studies are
opening up new opportunities for
research on FGFR2-associated diseases
(Easton et al., 2007; Hunter et al.,
2007). Here, FGFR2-associated disor-
ders or diseases are summarized in
Table 1, and then skin manifestations
caused by FGFR2 genetic alterations
are reviewed. As melanoma, squamous
cell carcinoma (SCC) and basal cell
carcinoma (BCC) are representative
skin malignancies, perspectives on
these malignancies are also described
with an emphasis on FGFR2 genetics.
HUMAN DISORDERS OR DISEASES
ASSOCIATED WITH FGFR2
Congenital skeletal disorders
FGFR2c is expressed on mesenchymal
cells during the early phase of long-
bone formation, known as the me-
senchymal condensation process.
FGFR2 is also expressed on preosteo-
blasts and osteoblasts during the later
phase of bone formation (Eswarakumar
et al., 2002). The nuclear factor-Y
transcription factor binds to the evolu-
tionarily conserved CCAAT motif in the
proximal promoter region of FGFR2
gene, and is involved in basal expres-
sion of FGFR2 (Sun et al., 2009). Bone
morphogenetic protein 2 induces
FGFR2 upregulation in C3H10T1/2
embryonic-fibroblast cells; however,
the mechanism of the FGFR2 induction
by bone morphogenetic protein-Smad
signaling remains unclear. As FGFR2 is
involved in bone formation, FGFR2 is a
causative gene for several congenital
skeletal disorders manifested by short-
limbed bone dysplasia or craniosynos-
tosis (Passos-Bueno et al., 1999; Kan
et al., 2002; Wilkie, 2005).
The FGFR2 gene is mutated in
Crouzon syndrome (Reardon et al.,
1994), Jackson–Weiss syndrome (Jabs
et al., 1994), Apert syndrome (Wilkie
et al., 1995), Pfeiffer syndrome (Rut-
land et al., 1995), Beare–Stevenson
syndrome (Przylepa et al., 1996), and
Saethre–Chotzen syndrome (Paznekas
et al., 1998). Missense mutations of
FGFR2 in congenital skeletal disorders
are clustered around the third immuno-
globulin-like domain or within the
tyrosine kinase domain (Figure 2).
Amino-acid substitutions around the
third immunoglobulin-like domain in-
duce autocrine FGFR2 activation
through altered FGF-binding specificity
(Yu et al., 2000), whereas those in the
tyrosine kinase domain induce ligand-
independent FGFR2 activation by the
releasing FGFR2 from autoinhibition
(Chen et al., 2007).
Breast cancer
Gene amplification of the FGFR2 gene
occurs in primary breast cancer (Ad-
nane et al., 1991). FGFR2 gene ampli-
fication results in overexpression of the
FGFR2 gene products, especially C-
terminally truncated FGFR2 protein,
because of the exclusion of the last
exon from the amplicon during the
gene amplification process (Katoh and
Katoh, 2003a). C-terminally truncated
FGFR2 induces constitutive activation
of FGFR2 signaling cascades in a
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Figure 1. FGFR2 signaling cascades. Fibroblast growth factor receptor (FGFR)2b functions as a receptor
for fibroblast growth factor (FGF)1, FGF3, FGF7, FGF10 and FGF22, whereas FGFR2c functions as a
receptor for FGF1, FGF2, FGF4, FGF6, FGF9, FGF16, FGF17, FGF18 and FGF20. FGFR2 transduces FGF
signals to Ras-extracellular signal-regulated kinase(ERK), phosphoinositide-3 kinase (PI3K)-Akt, Ca2þ ,
and diacylglycerol (DAG) signaling cascades. The FGF–ERK signaling cascade is involved in cell
proliferation. The FGF–PI3K signaling cascade is involved in cell survival and polarity control. Sprouty
inhibits the FGF–ERK signaling cascade at growth factor receptor-bound protein 2 and Raf, whereas dual-
specificity phosphatase inhibits the FGF–ERK signaling cascade at ERK. FGFR2 is regulated on the basis of
the balance of FGFs, heparan-sulfate proteoglycan (HSPG), FGFR2 isoforms, and endogenous inhibitors.
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ligand-independent manner (Moffa and
Ethier, 2007). R203C missense muta-
tion of the FGFR2 gene also occurs in
primary breast cancer (Stephens et al.,
2005). FGFR2 signaling is aberrantly
activated in breast cancer through
genetic alterations of FGFR2.
Genome-wide association studies
and candidate-approach association
studies showed that rs35054928,
rs2981578, rs2912778, rs2912781,
rs35393331, rs10736303, rs7895676,
and rs33971856 SNPs in intron 2 of the
FGFR2 gene are associated with breast
cancer (Easton et al., 2007; Huijts
et al., 2007; Hunter et al., 2007; Meyer
et al., 2008; Stacey et al., 2008). A
putative estrogen receptor (ER)-binding
site is created on the risk allele of
rs10736303 (Easton et al., 2007).
FGFR2 is preferentially upregulated in
ER-positive primary breast cancer
(Tozlu et al., 2006), and the FGFR2
risk allele is associated with ER-positive
breast cancer (Stacey et al., 2008).
Gastric cancer
Gastric cancer is classified into the
intestinal type and the diffuse type
(Lauren, 1965). The ERBB2 gene is
preferentially amplified in the intest-
inal-type gastric cancer, frequently
associated with liver metastasis,
whereas the FGFR2 gene is preferen-
tially amplified in the diffuse-type
gastric cancer, frequently associated
with peritoneal dissemination. The
two types of gastric cancer, with
distinct clinicopathological features,
show type-specific genetic alterations
(Katoh and Terada, 1993; Katoh and
Katoh, 2004).
FGFR2 signaling is aberrantly acti-
vated in diffuse-type gastric cancer
because of gene amplification or mis-
sense mutations (Nakatani et al., 1990;
Jang et al., 2001). Small-molecule FGFR
inhibitor Ki23057 inhibits proliferation
and peritoneal dissemination of gastric
cancer cells with FGFR2 gene amplifi-
cation, mainly by inhibitory effects on
the MAPK signaling cascade (Nakamura
et al., 2006). Small-molecule FGFR
inhibitors PD173074 and AZD2171
also show similar effects (Mohammadi
et al., 1998; Wedge et al., 2005).
The association between SNPs in
intron 2 of the FGFR2 gene and diffuse-
type gastric cancer remains unknown.
As diffuse-type gastric cancer is en-
riched in reproductive females, it is
speculated that diffuse-type gastric
cancer might be associated with ER
signaling at least in reproductive
females. Therefore, large-scale strati-
fied analyses should be carried out on
FGFR2 SNPs and ER status in diffuse-
type gastric cancer.
Endometrial uterine cancer
Missense mutations of the FGFR2 gene
also occur in endometrial uterine can-
cer, resulting in amino-acid substitu-
tions around the third immunoglobulin-
like domain (S252W, K310R, S373C,
Y376C, C383R, M392R), and those in
the tyrosine-kinase domain (I547V,
N549K, K659E) (Pollock et al., 2007).
These FGFR2 mutations result in aber-
rant activation of FGFR2 signaling as
mentioned above. The small-molecule
FGFR inhibitor PD173074 inhibits pro-
liferation and survival of endometrial
uterine-cancer cells with FGFR2 muta-
tions (Dutt et al., 2008).
The breast cancer risk allele of
rs2981578 SNP in intron 2 of the
FGFR2 gene is associated with a
decreased, rather than increased, risk
of endometrial uterine cancer
(McGrath et al., 2008). As the uterus
is an estrogen-responsive organ, large-
scale stratified analyses should also be
carried out on FGFR2 SNPs and ER
status in endometrial uterine cancer.
CUTANEOUS PHENOTYPES OF
FGFR2 ALTERATION OR VARIATION
Cutaneous FGFR2b
FGFR2b is expressed in epidermal
keratinocytes, hair follicles, and sebac-
eous glands (Danilenko et al., 1995;
auf demKeller et al., 2004). FGF7,
FGF10, and FGF22 are FGFR2b ligands
secreted by fibroblast, smooth muscle
cells, endothelial cells, skin dermis,
and gdT cells to induce proliferation
and differentiation of epidermal kerati-
nocytes (Finch et al., 1989; Smola
et al., 1993; Boismenu and Havran,
1994; Winkles et al., 1997; Marchese
et al., 2001). For example, FGF7
expression in mesenchymal cells is
upregulated by platelet-derived growth
factor derived from platelets and by IL-
1, IL-1b and tumor necrosis factor-a
derived from polymorphonuclear leu-
kocytes or macrophages (Werner et al.,
1992; Brauchle et al., 1994; Chedid
et al., 1994). FGFR2b ligands are
Table 1. Genetic variations and alterations of FGFR2
Disease Germ or
soma
Genetic alteration
or variation
Reference
Cancer
Breast cancer Somatic Copy-number gain Adnane et al. (1991)
Somatic Missense mutation Stephens et al. (2005)
Germ-line Intronic regulatory SNPs Easton et al. (2007)
Gastric cancer Somatic Copy-number gain Nakatani et al. (1990)
Somatic Missense mutation Jang et al. (2001)
Endometrial uterus cancer Somatic Missense mutation Pollock et al. (2007)
Lung cancer Somatic Missense mutation Davies et al. (2005)
Melanoma Somatic Missense mutation Gartside et al. (2009)
Non-cancerous disease
Crouzon syndrome Germ-line Missense mutation Reardon et al. (1994)
Jackson–Weiss syndrome Germ-line Missense mutation Jabs et al. (1994)
Apert syndrome Germ-line Missense mutation Wilkie et al. (1995)
Pfeiffer syndrome Germ-line Missense mutation Rutland et al. (1995)
Beare–Stevenson syndrome Germ-line Missense mutation Przylepa et al. (1996)
Saethre–Chotzen syndrome Germ-line Missense mutation Paznekas et al. (1998)
Atopic dermatitis Germ-line Intronic marker SNPs Park et al. (2008)
FGFR2, fibroblast growth factor receptor 2; SNPs, single-nucleotide polymorphisms.
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upregulated in the skin by cytokines
and growth factors during physiological
and pathological processes (auf dem-
Keller et al., 2004).
Melanoma
Recently, missense mutations of
FGFR2c around the third immunoglo-
bulin-like domain or in the tyrosine-
kinase domain were also reported
in melanoma (Gartside et al., 2009).
FGFR2c mutations in melanoma
around the third immunoglobulin-like
domain are involved in altered ligand
specificity, which is similar to conge-
nital skeletal diseases and other types
of cancer (Figure 2). FGFR2c mutations
in melanoma in the tyrosine kinase
domain, such as D530N, I642V, and
A648T, are associated with decreased,
rather than increased, kinase activity
in vitro, but they are not associated
with decreased tumorigenicity in vivo
(Gartside et al., 2009). The D530N
mutation is predicted to affect the
structure of the kinase hinge, whereas
I642V and A648T mutations are pre-
dicted to affect the structure of the
autophosphorylation loop (Figure 2).
Mouse cutaneous SCC
Epidermal growth and hair-follicle
morphogenesis are severely hampered
in the skin of the germline-Fgfr2b-
knockout mice (Revest et al., 2001;
Petiot et al., 2003). Conditional-knock-
out technology expressing Cre
recombinase under the control of bo-
vine keratin 5 promoter (Cre-K5) in
FGFR2bflox/flox mice was then applied
to elucidate the role of FGFR2b
during skin homeostasis. Mice lacking
FGFR2b in the skin epidermis manifest
a thin and silky coat, sebaceous
gland atrophy, increased macrophage
infiltration to the dermis and the
adipose tissue, and epidermal thicken-
ing accompanied by basal-layer dys-
plasia and parakeratosis (Grose et al.,
2007).
Conditional-FGFR2b knockout in
the skin epidermis leads to an in-
creased incidence of SCC in mice
treated with 7,12-dimethylbenz[a]an-
thracene and 12-O-tetradecanoylphor-
bol-13-acetate (Grose et al., 2007).
Intraepithelial gdT cells are involved
in the production of FGFR2 ligand
during the wound-healing process,
and mice lacking gdT cells also show
an increased incidence of 7,12-di-
methylbenz[a]anthracene/12-O-tetra-
decanoylphorbol-13-acetate-induced
SCC (Girardi et al., 2001). As FGFR2b
is involved in the maintenance of
cutaneous homeostasis and in wound
healing, inactivation of FGFR2b results
in enhanced sensitivity of the mouse
skin to chemical carcinogenesis.
Acne
The FGFR2 gene is mutated in Apert
syndrome, as mentioned above (Wilkie
et al., 1995). Apert-syndrome patients
with craniosynostosis show early onset
of severe acne, spreading in an unusual
pattern to the extensor aspects of the
forearms (Solomon et al., 1970). Epi-
dermal FGFR2 mutations because of
genetic mosaicism also result in severe
acne, which is characterized as uni-
lateral acneiform nevus (Munro and
Wilkie, 1998).
As androgen receptor (AR)-induced
upregulation of FGF7 or FGF10 in skin
mesenchymal cells results in FGFR2b
activation in the sebaceous gland,
FGFR2 is predicted to be involved in
the pathogenesis of acne (Melnik and
Schmitz, 2008).
Cutis gyrata and acanthosis nigricans
The FGFR2 gene is mutated in
Beare–Stevenson syndrome, as men-
tioned above (Przylepa et al.,
1996). Beare–Stevenson syndrome is
featured by craniosynostosis and skin
phenotypes, such as cutis gyrata
and acanthosis nigricans (Hall et al.,
1992). Cutis gyrata is characterized by
skin furrows of corrugated appearance,
particularly on the face, near the ears,
and sometimes on the palms and soles.
Acanthosis nigricans is characterized
by pigmented velvety areas on the
hands, feet, or genital region. The
mechanisms by which cutis gyrata
and acanthosis nigricans are induced
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Figure 2. Domain architecture and mutations of FGFR2. Fibroblast growth factor receptor (FGFR)2b and
FGFR2c are transmembrane-type receptors with extracellular immunoglobulin-like domains and
cytoplasmic tyrosine-kinase domain. Wild-type FGFR2 kinase is autoinhibited in the absence of FGF
signaling by the kinase hinge, constituted by N549, E565 and K641, and it is activated in the presence of
FGF signaling by autophosphorylation of Y657 in the activation loop. Missense mutations around the
third immunoglobulin-like domain results in altered ligand affinity. Some missense mutations in the
kinase domain increase the kinase activity in congenital skeletal disorders and in endometrial cancer,
whereas other missense mutations in the kinase domain decrease kinase activity at least in vitro.
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by the FGFR2 mutations remain
unclear.
Atopic dermatitis
Atopic dermatitis is a chronic, relap-
sing, inflammatory skin disorder char-
acterized by enhanced IgE responses to
common environmental allergens
(Cooper, 1994). Genetic predisposition
and environmental insult result in al-
tered epidermal structure and function,
and the hyper-activated immune system
then disrupts skin-barrier homeostasis
(Elias and Steinhoff, 2008). On the basis
of a candidate-approach association
study using 525 cases of atopic derma-
titis, it was recently claimed that a
haplotype of SNPs in intron 17 of the
FGFR2 gene is associated with atopic
dermatitis with a P-value of 0.01 (Park
et al., 2008). As the association is not
strong, a large-scale confirmatory study
is necessary to draw conclusions.
PERSPECTIVES ON THE
DERMATOLOGICAL GENETICS
OF FGFR2
Melanoma
FGFR2c mutations identified in mela-
noma are informative for understanding
the regulatory mechanisms of FGFR2
kinase (Figure 2). However, as FGF2
signaling through FGFR1c plays a pivo-
tal role in the proliferation and survival
of melanoma cells (Halaban, 1996;
Wang and Becker, 1997), loss-of-func-
tion mutations of FGFR2c in melanoma
might be passenger mutations. Bi-allelic
analyses of FGFR2c mutations or dele-
tions in human melanoma, as well as
in vivo analyses using conditional
FGFR2-knockout and a mutant FGFR2c
transgenic mouse model, are necessary
to elucidate the biological role of
FGFR2c mutations in melanoma.
Human cutaneous SCC
As mouse genetics indicates that
FGFR2b functions as a tumor suppres-
sor in the skin epidermis, as mentioned
above, it is predicted that decreased
FGFR2b signaling is favorable for the
development of SCC in human skin.
Breast cancer risk alleles of FGFR2
SNPs might be inversely correlated
with the risk of human cutaneous
SCC. Alternatively, deletions or loss-
of-function mutations of the FGFR2
gene might occur in human cutaneous
SCC. Therefore, genetic and genomic
analyses of the FGFR2 gene are neces-
sary to clarify the association between
FGFR2b inactivation and human cuta-
neous SCC.
BCC
BCC is one of most common malig-
nancies among Caucasians (Bastiaens
et al., 1998). BCC occurs because of
genetic predispositions and environ-
mental insults by UV light. Nevoid
basal cell carcinoma syndrome is char-
acterized by cutaneous BCC, epidermal
cysts, palmar pits, jaw keratocysts,
calcified dural folds, skeletal anoma-
lies, cleft lip, and other tumors such as
medulloblastoma and meningioma
(Gorlin, 1995). Loss-of-function muta-
tions of the patched/PTCH1 gene and
gain-of-function mutations of the
smoothened/SMO gene occur in nevoid
basal cell carcinoma syndrome, as well
as in sporadic BCC (Gailani et al., 1996;
Hahn et al., 1996; Johnson et al., 1996;
Reifenberger et al., 1998; Wicking
et al., 1999). Patched is a receptor for
the hedgehog family members (Stone
et al., 1996), whereas smoothened is a
signal transducer of the hedgehog
signaling cascade (van den Heuvel
and Ingham, 1996). Hedgehog signal-
ing activation is the driving force of
BCC (Epstein, 2008). As the FGF–
FGFR2b signaling cascade cross-talks
with the hedgehog signaling cascade
(Bellusci et al., 1997; Revest et al.,
2001; Spencer-Dene et al., 2006), the
combined effects of FGFR2 SNPs and
environmental factors in BCC should be
further investigated in the future.
CONCLUDING REMARKS
The identification of a large number of
mutations in the FGFR2 gene has
provided fascinating insight into the
etiology of several skin and bone
diseases, as well as some malignancies.
The spectrum of disorders is under-
scored by a range of germline or
somatic gain-of-function mutations or
loss-of-function mutations in FGFR2.
With regard to carcinogenesis, FGFR2
can have a dual role, acting either as an
oncogene or as a tumor-suppressor
gene. Observations in rodent models
that oral administration of AZD2171 or
Ki23057 inhibits in vivo proliferation of
cancer cells with aberrant FGFR2
signaling activation provide a rationale
for exploring the therapeutic potential
of similar FGFR2 inhibitors in humans
with malignancies associated with ac-
tivating FGFR2 mutations or FGFR2
gene amplification. Nevertheless,
FGFR2 inhibitors have the potential to
disrupt several beneficial homeostatic
processes, including cytoprotective
mechanisms against environmental in-
sults, such as UV irradiation, X-ray
irradiation, chronic infection, and
tobacco smoke. Consequently, any
future pre-clinical studies on FGFR2
inhibitors will carefully need to con-
sider the risk–benefit ratio, notwith-
standing the considerable therapeutic
modification these drugs might have on
disease and tumor biology.
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